VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$321.37

Market cap

$82.49B

P/E Ratio

25.11

Dividend/share

N/A

EPS

$12.8

Enterprise value

$74.15B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The EPS has surged by 52% year-on-year and by 2.6% since the previous quarter
Vertex Pharmaceuticals's net income has surged by 50% YoY and by 2.5% QoQ
The price to earnings (P/E) is 46% less than the 5-year quarterly average of 46.2 but 3.8% more than the last 4 quarters average of 24.2

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
256.69M
Market cap
$82.49B
Enterprise value
$74.15B
Valuations
Price to earnings (P/E)
25.11
Price to book (P/B)
6.33
Price to sales (P/S)
9.47
EV/EBIT
18.15
EV/EBITDA
17.53
EV/Sales
8.52
Earnings
Revenue
$8.7B
EBIT
$4.08B
EBITDA
$4.23B
Free cash flow
$3.81B
Per share
EPS
$12.8
Free cash flow per share
$14.87
Book value per share
$50.81
Revenue per share
$33.92
TBVPS
$58.59
Balance sheet
Total assets
$16.71B
Total liabilities
$3.68B
Debt
$824.6M
Equity
$13.03B
Working capital
$9.66B
Liquidity
Debt to equity
0.06
Current ratio
4.7
Quick ratio
4.28
Net debt/EBITDA
-1.97
Margins
EBITDA margin
48.6%
Gross margin
88%
Net margin
37.6%
Operating margin
47%
Efficiency
Return on assets
21.8%
Return on equity
28.5%
Return on invested capital
103.5%
Return on capital employed
29%
Return on sales
46.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.19%
1 week
2.68%
1 month
3.66%
1 year
57.19%
YTD
46.34%
QTD
10.99%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$8.7B
Gross profit
$7.66B
Operating income
$4.09B
Net income
$3.27B
Gross margin
88%
Net margin
37.6%
The operating income has surged by 54% year-on-year
Vertex Pharmaceuticals's net income has surged by 50% YoY and by 2.5% QoQ
The operating margin has increased by 26% YoY but it has decreased by 2.5% QoQ
VRTX's net margin is up by 23% YoY

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
25.11
P/B
6.33
P/S
9.47
EV/EBIT
18.15
EV/EBITDA
17.53
EV/Sales
8.52
The EPS has surged by 52% year-on-year and by 2.6% since the previous quarter
The price to earnings (P/E) is 46% less than the 5-year quarterly average of 46.2 but 3.8% more than the last 4 quarters average of 24.2
The equity has grown by 37% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 33% less than its 5-year quarterly average of 9.5 but 9% more than its last 4 quarters average of 5.8
VRTX's revenue is up by 22% YoY and by 4.2% QoQ
The price to sales (P/S) is 20% less than the 5-year quarterly average of 11.9 but 14% more than the last 4 quarters average of 8.3

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital rose by 33% year-on-year
VRTX's return on assets is up by 22% year-on-year but it is down by 4.8% since the previous quarter
The return on sales has increased by 19% year-on-year
The return on equity has grown by 19% year-on-year but it has declined by 5% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 32% YoY and by 7% QoQ
The total liabilities has increased by 19% YoY
VRTX's debt is 94% lower than its equity
The equity has grown by 37% YoY and by 9% from the previous quarter
The debt to equity fell by 33% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.